References

• Agarwal, V., Sitholey, P., & Srivastava, C. (2019). Clinical practice guidelines for the management of dissociative disorders in children and adolescents. Indian Journal of Psychiatry, 61(Suppl 2), 247–253. https://doi.org/10.4103/psychiatry.IndianJPsychiatry_493_18
   PubMedGoogle Scholar
• American Psychiatric Association. (2014). DSM-5: Manual diagnóstico y estadístico de los trastornos mentales. Editorial Médica Panamericana.
   Google Scholar
• Bandelow, B., Schmahl, C., Falkai, P., & Wedekind, D. (2010). Borderline personality disorder: A dysregulation of the endogenous opioid system? Psychological Review, 117(2), 623–636. https://doi.org/10.1037/a0018095
   PubMed Web of Science ®Google Scholar
• Berg, B. J., Pettinati, H. M., & Volpicelli, J. R. (1996). A risk-benefit assessment of naltrexone in the treatment of alcohol dependence. Drug Safety, 15(4), 274–282. https://doi.org/10.2165/00002018-199615040-00005
   PubMed Web of Science ®Google Scholar
• Bernstein, E. M., & Putnam, F. W. (1986). Development, reliability, and validity of a dissociation scale. Journal of Nervous and Mental Disease, 174(12), 727–735. https://doi.org/10.1097/00005053-198612000-00004
   PubMed Web of Science ®Google Scholar
• Bob, P. (2008). Pain, dissociation and subliminal self-representations. Consciousness and Cognition, 17(1), 355–369. https://doi.org/10.1016/j.concog.2007.12.001
   PubMed Web of Science ®Google Scholar
• Bohus, M. J., Landwehrmeyer, G. B., Stiglmayr, C. E., Limberger, M. F., Böhme, R., & Schmahl, C. G. (1999). Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: An open-label trial. The Journal of Clinical Psychiatry, 60(9), 598–603. https://doi.org/10.4088/jcp.v60n0906
   PubMed Web of Science ®Google Scholar
• Bolm, T., & Piegler, T. (2001). Der Einsatz von Naltrexon bei dissoziativen Störungen–Uberlegungen zu einem Gesamtkonzept von Borderlinebehandlungen [Naltrexone in the treatment of dissociative disorders–reflections with regard to a comprehensive therapeutic concept of borderline disorders]. Psychiatrische Praxis, 28(5), 214–218. https://doi.org/10.1055/s-2001-15573
   PubMedGoogle Scholar
• Brand, B., Classen, C., Lanins, R., Loewenstein, R., McNary, S., Pain, C., & Putnam, F. (2009). A naturalistic study of dissociative identity disorder and dissociative disorder not otherwise specified patients treated by community clinicians. Psychological Trauma: Theory, Research, Practice, and Policy, 1(2), 153–171. https://doi.org/10.1037/a0016210
   Web of Science ®Google Scholar
• Bremner, J. D., Krystal, J. H., Putnam, F. W., Southwick, S. M., Marmar, C., Charney, D. S., & Mazure, C. M. (1998). Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). Journal of Traumatic Stress, 11(1), 125–136. https://doi.org/10.1023/A:1024465317902
   PubMed Web of Science ®Google Scholar
• Carlezon, W. A., Jr, Béguin, C., Knoll, A. T., & Cohen, B. M. (2009). Kappa-opioid ligands in the study and treatment of mood disorders. Pharmacology & Therapeutics, 123(3), 334–343. https://doi.org/10.1016/j.pharmthera.2009.05.008
   PubMed Web of Science ®Google Scholar
• Dorahy, M. J., Brand, B. L., Sar, V., Krüger, C., Stavropoulos, P., Martínez-Taboas, A., Lewis-Fernández, R., & Middleton, W. (2014). Dissociative identity disorder: An empirical overview. The Australian and New Zealand Journal of Psychiatry, 48(5), 402–417. https://doi.org/10.1177/0004867414527523
   PubMed Web of Science ®Google Scholar
• Enning, F., & Schmahl, C. (2022). Behandlung dissoziativer Symptome mit Nalmefen bei Patienten mit Borderline-Persönlichkeitsstörung und komplexer posttraumatischer Belastungsstörung [Treatment of dissociative symptoms with nalmefene in patients with borderline personality disorder and complex posttraumatic stress disorder]. Der Nervenarzt, 93(5), 503–505. https://doi.org/10.1007/s00115-021-01239-1
   PubMedGoogle Scholar
• Farina, B., Liotti, M., & Imperatori, C. (2019). The role of attachment trauma and disintegrative pathogenic processes in the traumatic-dissociative dimension. Frontiers in Psychology, 10, 933. https://doi.org/10.3389/fpsyg.2019.00933
   PubMed Web of Science ®Google Scholar
• Gainer, D. M., Crawford, T. N., Fischer, K. B., & Wright, M. D. (2021). The relationship between dissociative symptoms and the medications used in the treatment of opioid use disorder. Journal of Substance Abuse Treatment, 121, 108195. https://doi.org/10.1016/j.jsat.2020.108195
   PubMed Web of Science ®Google Scholar
• García, M. C. (2020). Tratamiento del Trastorno límite de la personalidad con antagonistas opioides: buprenorfina, nalmefeno, naloxona y naltrexona en el tratamiento de síntomas disociativos, automutilaciones y conducta suicida [Treatment of borderline personality disorder with opioid antagonists: buprenorphine, nalmefene, naloxone and naltrexone in the treatment of dissociative symptoms, self-mutilation and suicidal behavior]. Vertex (Buenos Aires, Argentina), XXX(148), 1–10.
   PubMedGoogle Scholar
• García, R. R., Rico, S. E. G., & Agráz, F. P. (2006). Disociative disorders in Mexican psychiatric patients: Prevalence, comorbidity and dissociative experiences scale psychometric properties. Salud Mental, 29(2), 38–43.
   Web of Science ®Google Scholar
• Gentile, J. P., Dillon, K. S., & Gillig, P. M. (2013). Psychotherapy and pharmacotherapy for patients with dissociative identity disorder. Innovations in Clinical Neuroscience, 10(2), 22–29.
   PubMedGoogle Scholar
• Ghafarinezhad, A., Rajabizadeh, G., & Shahriari, V. (2013). Relationships of dissociative disorders and personality traits in opium addicts on methadone treatment. Addiction & Health, 5(1-2), 21–26.
   PubMedGoogle Scholar
• Glover, H. (1993). A preliminary trial of nalmefene for the treatment of emotional numbing in combat veterans with post-traumatic stress disorder. The Israel Journal of Psychiatry and Related Sciences, 30(4), 255–263.
   PubMed Web of Science ®Google Scholar
• Higgins, J. P. T., & Green, S. (Eds.) (2011). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.handbook.cochrane.org.
   Google Scholar
• Holden, J. E., Jeong, Y., & Forrest, J. M. (2005). The endogenous opioid system and clinical pain management. AACN Advanced Critical Care, 16(3), 291–301.
   Google Scholar
• International Society for the Study of Trauma and Dissociation. (2011). Guidelines for treating dissociative identity disorder in adults, third revision. Journal of Trauma & Dissociation, 12(2), 115–187. https://doi.org/10.1080/15299732.2011.537247
   PubMed Web of Science ®Google Scholar
• Johnson, B. A., & Ait-Daoud, N. (1999). Medications to treat alcoholism. Alcohol Research & Health: The Journal of the National Institute on Alcohol Abuse and Alcoholism, 23(2), 99–106.
   PubMedGoogle Scholar
• Klonsky, E. D. (2007). The functions of deliberate self-injury: A review of the evidence. Clinical Psychology Review, 27(2), 226–239. https://doi.org/10.1016/j.cpr.2006.08.002
   PubMed Web of Science ®Google Scholar
• Lanius, R. A., Boyd, J. E., McKinnon, M. C., Nicholson, A. A., Frewen, P., Vermetten, E., Jetly, R., & Spiegel, D. (2018). A review of the neurobiological basis of trauma-related dissociation and its relation to cannabinoid- and opioid-mediated stress response: A transdiagnostic, translational approach. Current Psychiatry Reports, 20(12), 118. https://doi.org/10.1007/s11920-018-0983-y
   PubMed Web of Science ®Google Scholar
• Lanius, U. F. (2014). Dissociation and endogenous opioids: A foundational role. En U. F. Lanius, S. L. Paulsen, & F. M. Corrigan (Eds.), Neurobiology and treatment of traumatic dissociation: Towards an embodied self (pp. 81–104). Springer Publishing Company.
   Google Scholar
• Lanius, U. F., Paulsen, S. L., & Corrigan, F. M. (Eds.). (2014). Neurobiology and treatment of traumatic dissociation: Towards an embodied self. Springer Publishing Company.
   Google Scholar
• Lubin, G., Weizman, A., Shmushkevitz, M., & Valevski, A. (2002). Short-term treatment of post-traumatic stress disorder with naltrexone: An open-label preliminary study. Human Psychopharmacology, 17(4), 181–185. https://doi.org/10.1002/hup.395
   PubMed Web of Science ®Google Scholar
• Lyssenko, L., Schmahl, C., Bockhacker, L., Vonderlin, R., Bohus, M., & Kleindienst, N. (2018). Dissociation in psychiatric disorders: A meta-analysis of studies using the dissociative experiences scale. The American Journal of Psychiatry, 175(1), 37–46. https://doi.org/10.1176/appi.ajp.2017.17010025
   PubMed Web of Science ®Google Scholar
• Maldonado, J. R., Butler, L. D., & Spiegel, D. (2002). Treatments for dissociative disorders. In P. E. Nathan & J. M. Gorman (Eds.), A guide to treatments that work (pp. 463–496). Oxford University Press.
   Google Scholar
• Marrazzi, M. A., Bacon, J. P., Kinzie, J., & Luby, E. D. (1995). Naltrexone use in the treatment of anorexia nervosa and bulimia nervosa. International Clinical Psychopharmacology, 10(3), 163–172. https://doi.org/10.1097/00004850-199510030-00005
   PubMed Web of Science ®Google Scholar
• Martín-Blanco, A., Patrizi, B., Soler, J., Gasol, X., Elices, M., Gasol, M., Carmona, C., & Pascual, J. C. (2017). Use of nalmefene in patients with comorbid borderline personality disorder and alcohol use disorder: A preliminary report. International Clinical Psychopharmacology, 32(4), 231–234. https://doi.org/10.1097/YIC.0000000000000170
   PubMed Web of Science ®Google Scholar
• Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2010). Preferred reporting items for systematic reviews and metaanalyses: The PRISMA statement. International Journal of Surgery, 8(5), 336–341. https://doi.org/10.1016/j.ijsu.2010.02.007
   PubMed Web of Science ®Google Scholar
• Mosquera, D. (2013). Diamantes en bruto: Un acercamiento al trastorno límite de la personalidad: manual informativo para profesionales, pacientes y familiares. Pléyades.
   Google Scholar
• Nuller, Y. L., Morozova, M. G., Kushnir, O. N., & Hamper, N. (2001). Effect of naloxone therapy on depersonalization: A pilot study. Journal of Psychopharmacology, 15(2), 93–95. https://doi.org/10.1177/026988110101500205
   PubMed Web of Science ®Google Scholar
• Oncken, C., Van Kirk, J., & Kranzler, H. R. (2001). Adverse effects of oral naltrexone: Analysis of data from two clinical trials. Psychopharmacology, 154(4), 397–402. https://doi.org/10.1007/s002130000666
   PubMed Web of Science ®Google Scholar
• Pape, W. (2020). Dissociative Disorders in L. Elsegood (ed.) The LDN Book, Volume Two: The latest research on how Low Dose Naltrexone could revolutionize treatment for PTSD, Pain, IBD, Lyme Disease, Dermatologic Conditions, and more. Chelsea Green, London, UK.
   Google Scholar
• Pape, W., & Wöller, W. (2015). Niedrig dosiertes naltrexon in der behandlung dissoziativer symptome [Low dose naltrexone in the treatment of dissociative symptoms]. Der Nervenarzt, 86(3), 346–351. https://doi.org/10.1007/s00115-014-4015-9
   PubMedGoogle Scholar
• Perry, B., & Szalavitz, M. (2017). El chico a quien criaron como perro: Y otras historias del cuaderno de un psiquiatra infantil. Capitán Swing Libros.
   Google Scholar
• Philipsen, A., Schmahl, C., & Lieb, K. (2004). Naloxone in the treatment of acute dissociative states in female patients with borderline personality disorder. Pharmacopsychiatry, 37(5), 196–199. https://doi.org/10.1055/s-2004-827243
   PubMed Web of Science ®Google Scholar
• Putnam, F. W., Hornstein, N., & Peterson, G. (1996). Clinical phenomenology of child and adolescent dissociative disorders: Gender and Age effects. Child and Adolescent Psychiatric Clinics of North America, 5(2), 351–360. https://doi.org/10.1016/S1056-4993(18)30370-5
   Web of Science ®Google Scholar
• Romero-López, M. J. (2016). Una revisión de los trastornos disociativos; de la personalidad múltiple al estrés postraumático. Anales De Psicología/Annals of Psychology, 32(2), 448–456. https://doi.org/10.6018/analesps.32.2.218301
   Google Scholar
• Roth, A. S., Ostroff, R. B., & Hoffman, R. E. (1996). Naltrexone as a treatment for repetitive self-injurious behaviour:An open-label trial. The Journal of Clinical Psychiatry, 57(6), 233–237.
   PubMed Web of Science ®Google Scholar
• Schmahl, C., Kleindienst, N., Limberger, M., Ludäscher, P., Mauchnik, J., Deibler, P., Brünen, S., Hiemke, C., Lieb, K., Herpertz, S., Reicherzer, M., Berger, M., & Bohus, M. (2012). Evaluation of naltrexone for dissociative symptoms in borderline personality disorder. International Clinical Psychopharmacology, 27(1), 61–68. https://doi.org/10.1097/YIC.0b013e32834d0e50
   PubMed Web of Science ®Google Scholar
• Sierra, M., & Berrios, G. E. (2000). The Cambridge depersonalisation scale: A new instrument for the measure of depersonalization. Psychiatry Research, 93(2), 153–164. https://doi.org/10.1016/S0165-1781(00)00100-1
   PubMed Web of Science ®Google Scholar
• Simeon, D., & Knutelska, M. (2005). An open trial of naltrexone in the treatment of depersonalization disorder. Journal of Clinical Psychopharmacology, 25(3), 267–270. https://doi.org/10.1097/01.jcp.0000162803.61700.4f
   PubMed Web of Science ®Google Scholar
• Somer, E., Altus, L., & Ginzburg, K. (2010). Dissociative psychopathology among opioid use disorder patients: Exploring the “chemical dissociation” hypothesis. Comprehensive Psychiatry, 51(4), 419–425. https://doi.org/10.1016/j.comppsych.2009.09.007
   PubMed Web of Science ®Google Scholar
• Spitzer, C., & Freyberger, H. J. (2008). Geschlechtsunterschiede bei dissoziativen Störungen [Gender differences in dissociative disorders]. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 51(1), 46–52. https://doi.org/10.1007/s00103-008-0418-8
   PubMed Web of Science ®Google Scholar
• Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbet,t, M. S., Eldridge, S. M., Hernán, M. A., Hopewell, S., Hróbjartsson, A., Junqueira, D. R., Jüni, P., Kirkham, J. J., Lasserson, T., Li, T., McAleenan, A., … Higgins, J. P. T. (2019). RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ, 366: l4898. Retrieved July 15, 2022, from https://sites.google.com/site/riskofbiastool/welcome/rob-2-0-tool?authuser = 0.
   Google Scholar
• Stiglmayr, C. E., Shapiro, D. A., Stieglitz, R. D., Limberger, M. F., & Bohus, M. (2001). Experience of aversive tension and dissociation in female patients with borderline personality disorder – a controlled study. Journal of Psychiatric Research, 35(2), 111–118. https://doi.org/10.1016/s0022-3956(01)00012-7
   PubMed Web of Science ®Google Scholar
• Sutar, R., & Sahu, S. (2019). Pharmacotherapy for dissociative disorders: A systematic review. Psychiatry Research, 281, 112529. https://doi.org/10.1016/j.psychres.2019.112529
   PubMed Web of Science ®Google Scholar
• Şar, V. (2022). Dissociation across cultures: A transdiagnostic guide for clinical assessment and management. Alpha Psychiatry, 23(3), 95–103. https://doi.org/10.5152/alphapsychiatry.2022.21556
   PubMedGoogle Scholar
• Timäus, C., Meiser, M., Wiltfang, J., Bandelow, B., & Wedekind, D. (2021). Efficacy of naltrexone in borderline personality disorder, a retrospective analysis in inpatients. Human Psychopharmacology, 36(6), e2800. https://doi.org/10.1002/hup.2800
   PubMed Web of Science ®Google Scholar
• Wells, G., Shea, B., O’Connell, D., Peterson, J., Welch, V., Losos, M., & Tugwell, P. (2019). The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Metaanalyses. 2019. Retrieved July 15, 2022, from http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
   Google Scholar